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ABSTRACT 
Background: CD1d presents glycolipid antigens to invariant natural killer T (iNKT) 
cells. The role of CD1d in the development of peptic ulcer and gastric cancer has not 
been revealed, yet. Objective: To clarify the expression of alternatively spliced variants 
of CD1d in peptic ulcer and gastric cancer. Methods: Patients with dyspepsia were 
selected and divided into three groups of non-ulcer dyspepsia (NUD), peptic ulcer 
disease (PUD), and gastric cancer (GC), according to their endoscopic and 
histopathological examinations. H. pylori infection was diagnosed by rapid urease test 
and histopathology. The expression levels of V2, V4, and V5 spliced variants of CD1d 
molecule were determined by quantitative Reverse Transcriptase PCR. Results: 
Relative gene expression levels of V4 were higher in GC patients (n=37) than those in 
NUD (n=49) and PUD (n=51) groups (p<0.05 and p<0.01, respectively). Moreover, GC 
patients showed higher expression levels of V5 compared to NUD and PUD groups 
(p<0.001 and p<0.001, respectively). Positive correlation coefficients were attained 
between V4 and V5 expression in patients with PUD (r=0.734, p<0.0001) and GC 
(r=0.423, p<0.01), but not in patients with NUD. Among NUD patients, the expression 
levels of V4, but not V5, were higher in H. pylori-positive patients than in H. pylori-
negative ones (p<0.01). Conclusion: Collectively, both membrane-bound (V4) and 
soluble (V5) isoforms of CD1d were over-expressed in gastric tumor tissues, suggesting 
that they are involved in anti-tumor immune responses.  
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INTRODUCTION 
Peptic ulcer disease (PUD) and gastric cancer (GC) are common diseases worldwide 
(1,2). Helicobacter pylori has been recognized as a main risk factor for the development 
of PUD and GC (3,4). Most of the infected individuals (80-90%) carry and spread the 
bacterium while they are asymptomatic, while others develop one of the two clinical
outcomes, PUD and GC. The reasons for developing these two extreme outcomes have
not been clearly understood (4). It has been reported that colonization of H. pylori in
human gastric mucosa activates innate immune responses by gastric epithelial cells 
which can lead to adaptive immune responses (5). Moreover, interaction between H. 
pylori surface antigens and receptors of innate immune cells inside the gastric mucosa
might determine the pathological outcome of H. pylori infection, including development 
of PUD or GC (5). On the other hand, H. pylori can evade the immune system via 
suppression of innate immune responses; this might lead to active survival of bacteria in 
local mucosal environment, which, in turn, affects the development of mentioned 
pathological conditions (6). Therefore, study of cells and molecules involved in innate 
immunity can lead to better understanding of innate immune circumstances resulting in 
peptic ulcer and gastric cancer. 
Invariant Natural Killer T (iNKT) cells are innate T lymphocytes that express an 
invariant TCR α chain and recognize glycolipid antigens mostly presented by CD1d 
molecules (7). The frequency of iNKT cells in human gastric mucosa has been shown to 
be higher in H. pylori infected subjects compared to non-infected individuals (8). 
Moreover, one study showed that cholesteryl α-glucosides, which constitute 25% of
total H. pylori lipids, can be bound with CD1d, and induce an immune response by 
iNKT cells, thus causing inflammation in gastric mucosa (9).  
CD1d molecule is a membranous glycoprotein which has many structural similarities 
with histocompatibility class 1 (MHC-I) genes, both encode transmembrane proteins 
type 1 (α heavy chain) with three extracellular domains, α1, α2, and α3, associated non-
covalently to β2 microglobulin (β2M) (10). CD1d is expressed on a variety of immune
cells including dendritic cells, B cells, and T cells (10), as well as on different epithelial 
cells (11-13), where it presents glycolipid antigens to innate immune cells, mainly iNKT 
cells (14). Benam et al. investigated the expression of the six alternatively spliced 
variants of CD1d in human bronchial epithelial cells and showed that these variants are 
specific to epithelial cells (15). Among these alternative spliced variants of CD1d, only 
V2, V4, and V5 seem to be able to bind antigens because they preserve their antigen 
binding domains (α1 and α2) (Figure 1). According to that study, V2 is deficient in the 
trans-membrane (TM) domain, while V4 and V5 lack α3 and α3-TM domains, 
respectively (15). Therefore, V2 and V5 represent the soluble forms, while V4 
represents the membranous form (15). In the present study, V2, V4, and V5 were 
selected to be investigated, since, all three variants contain intact α1 and α2 domains 
forming antigen binding region, thereby likely capable of presenting glycolipid 
antigens.  
Since CD1d is an innate immune receptor on different epithelial cells which can 
recognize H. pylori lipid antigens, and given the role of H. pylori recognition by gastric
epithelial cells in the development of mucosal inflammation and subsequent occurrence 
of gastritis, gastric ulcer, and gastric cancer, we hypothesized that there might be an 
association between the expression levels of CD1d spliced variants and development of 
dyspeptic disorders in H. pylori infected individuals. Therefore, this study aimed to 
Iran.J.Immunol. VOL.12 NO. 2 June 2015 130 
   
 
 
 
 
  
   
 
 
 
 
   
     
     
     
 
     
     
    
     
     
    
    
     
  
CD1d expression in Gastric cancer 
determine the expression levels of V2, V4, and V5 isoforms of CD1d molecule in 
gastric biopsy specimens of H. Pylori-positive and-negative patients with dyspeptic
disorders, including non-ulcer dyspepsia (NUD), PUD, and GC. 
MATERIALS AND METHODS  
Patients. Patients with dyspepsia, who underwent esophago-gastro-duodenoscopy at 
Imam Hospital or the Outpatient Clinic of Mazandaran University of Medical Sciences
(Sari, Iran), were enrolled in the study. All samples were taken between January 2012 
and December 2013. The study was approved by the Ethics Committee of Mazandaran 
University of Medical Sciences. Clinical history, demographic data, and written 
informed consent were taken from all study subjects. None of the subjects had a history 
of chronic inflammatory or autoimmune disorders, received non-steroidal anti-
inflammatory drugs (NSAIDs) during past two weeks, or had a history of H. pylori
eradication therapy. None of patients with GC had received surgery, radiotherapy, 
chemotherapy, or any other form of medical interventions before sample collection. 
Three tissue samples from the gastric antrum were taken from each patient during 
endoscopy. One of the tissue samples was applied for the rapid urease test and the
second one was fixed and processed for routine histopathological examination. Based 
on the endoscopic and histopathological assessments, samples were divided into three 
groups of non-ulcer dyspepsia (NUD), peptic ulcer disease (PUD), and gastric cancer 
(GC). The histological grade of the gastric tumors was determined on the basis of 
differentiation. The presence of H. pylori infection was determined by the rapid urease 
test and histopathological examination (including Giemsa staining). Patients were 
considered as H. pylori-positive if the results by at least one test was positive and H. 
pylori-negative if the results by both tests were negative.  
Table 1. Characteristics of the study subjects. 
Age (mean ± SD)
Sex Male
NUD (n=52) 
47.1 ± 14.6
13 (25.0%)
PUD (n=53) 
54.4 ± 18.5
24 (45.3%)
GC (n=39)
71.4 ± 10.6
32 (82.1%)
H. pylori 
Tumor Grade 
Female
Positive 
Negative
ND
G1
G2
G3
39 (75.0%)
30 (57.7%) 
19 (38.8%)
3 (5.8%)
29 (54.7%)
36 (67.9%) 
16 (30.2%)
1 (1.9%)
7 (17.9%)
20 (51.3%)
17 (43.6%)
2 (5.1%)
3 (7.7%) 
11 (28.2%)
20 (51.3%)
 G4
ND
0 (0%)
5 (12.8%)
NUD: Non-ulcer dyspepsia, PUD: Peptic ulcer disease, GC: Gastric cancer, ND: Not defined
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Patients in each of the three groups were then divided into two subgroups of H. pylori-
positive and -negative. Table 1 shows the demographic data of patients as well as the
histopathologic grading of gastric tumors. 
The third tissue sample from each patient was preserved in the RNase inactivating
solution (RNAlater, Qiagen, Germany) for RNA extraction. 
RNA Isolation and cDNA Synthesis. Each tissue specimen was homogenized using 
mortar and pestle at room temperature. Total RNA was extracted from 50 mg of 
dissected tissues using a commercial RNA extraction kit (RNeasyMinikit; Qiagen,
Germany), according to the manufacturer’s instructions. The quantity and quality of 
extracted RNAs were assessed by a nanodrop spectrophotometer (Thermo Fisher 
Scientific Inc., US) and agarose gel electrophoresis, respectively. RNA (1μg) was 
reverse-transcribed into complementary DNA (cDNA) using the RevertAidTMFirst-
Strand cDNA Synthesis Kit (Fermentas, Germany) primed with random hexamer primer 
as per the manufacturer’s instructions. 
Primer Designing. The sequences of CD1d and Hypoxanthine-guanine phospho­
ribosyl-transferase (HGPRT), as a normalizer, was obtained from the GenBank (Table 
2). Primers for amplification of HGPRT as well as V2, V4, and V5 spliced variants of 
CD1d were designed using the Beacon designer software and synthesized by TIBmol 
(Germany) (Table 2).  
Table 2. Primers and probes used for real-time PCR quantification. 
Gene
CD1d 
Genbank Accession 
Number
NM_001766 
Primers (5’-3’)* 
For. V2, GAA CTG AAG AAG CAA GTG AAG 
Rev. V2, CCT GAT AGG AAC CCA GTA GAG 
Product Size
(bp)
306 
For. V4, GCT ACG CTT ATC CTA TCC CTT G
Rev. V4, AGC TCC CAC CTT GCT TCT TC 302 
For. V5, GCT ACG CTT ATC CTA TCC CTT G
Rev. V5, GCC CTG ATA GGA ACT TGC TTC 306 
HGPRT NM_000194.2 For., CTA ATT ATG GAC AGG ACT GAA CGRev., TTG ACT GGT CAT TAC AAT AGC TC 211 
 For., forward primer; Rev., reverse primer. ٭ 
Based on Benam et al. (15),V2 lacks the trans-membrane (TM) domain, which is
encoded by exon 6. Thus, the primers for V2 were designed to amplify the entire exon 5 
along with the junction of exon 5 to exon 7. On the other hand, V4 lacks α3 domain 
encoded by exon 5. Therefore, the primers for V4 were designed to amplify the whole
exon 4 plus the junction of exon 4 to exon 6. The primers for V5 amplification were 
designed to amplify the whole exon 4 plus the junction of exon 4 to exon 7, as V5 is
deficient in α3 and TM domains encoded by exons 5 and 6, respectively (Figure 1).  
Quantitative Reverse Transcriptase Polymerase Chain Reaction. Quantitative 
reverse transcriptase polymerase chain reaction (qRT-PCR) was performed using 96 
well plates (Bio-Rad Laboratories Inc., USA) in a volume of 20 μL containing Maxima
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SYBR Green/ROX qPCR Master Mix (2X) (Thermo Scientific),10 pmols of each of 
forward and reverse primers, and 2 μL of cDNA. The samples were denatured at 95°C 
for 10 min, and amplified using 40 cycles of 95°C for 30 s, 55°C for 30 s, and 72°C for 
30s on an iQ5 real-time thermal cycler (Bio-Rad Laboratories Inc.). Ct (cycle of 
threshold) values corresponding to the number of PCR cycles at which the fluorescence 
emission monitored in real time exceeded a threshold limit (10× the standard deviation 
of the baseline intensity) were measured. A mean cycle of threshold (Ct) value for each 
duplicate measurement was calculated. Relative gene expression was then calculated 
using “ΔCt method using a reference gene” in the following manner for each sample: 
2Ct (reference) – Ct (target)Ratio (reference/target) = 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Graphical representation of CD1d mRNA and alternative spliced CD1d isoforms. The 
CD1d heavy chain contains α1, α2, α3, transmembrane (TM), and cytoplasmic tail domains, 
which are encoded by chromosome 1 and a light chain β2M molecule which is encoded by 
chromosome 15. Exons 3-5 encode α1-α3 domains, respectively. The antigen-binding site is 
composed by exons 3 and 4. V1 to V6 are six alternatively spliced isoforms of CD1d transcripts. 
V2 and V5 lack the TM domain and are thus represented as soluble isoforms. In contrast, V1, 
V3, V4, and V6 contain TM domain and are represented as membrane-bound isoforms. α2 in 
V3 and α2 and α3 in V6 are incomplete domains and thus illustrated with incomplete circles 
(This figure is illustrated based on information adopted from Benam et al. (15)). 
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Statistical Analysis. Statistical analysis was performed using the SPSS statistical 
package (SPSS, Chicago, IL, USA). The results were evaluated by independent-samples 
t-test, Mann-Whitney U test and Pearson and Spearman correlation tests where 
appropriate. The strength of association between the expression levels of CD1d variants
was analyzed using the Spearman rank order correlation test, and the correlation 
coefficient was calculated. Findings were considered significant when p-values were 
<0.05. The results presented in the text and tables represent geometric mean in case of 
2ΔCt and mean ± standard deviation (SD) in case of other variables. 
RESULTS 
Forty nine patients with NUD, 51 with PUD, and 37 with GC were enrolled in this 
study (Table 1). 
Increased Expression of V4and V5 in GC Patients. In order to measure the 
expression levels of V2, V4, and V5, cDNA form each tissue sample was individually 
amplified using the primer pairs for V2, V4, and V5 as well as for HGPRT as a
normaliser. Relative expression levels of V2, V4, and V5 were then calculated by “ΔCt 
method, using a reference gene” as mentioned above. As Figure 2 shows, relative
expression levels of V4 were higher in GC patients than those of NUD and PUD groups
(p<0.05 and p<0.01, respectively) (Figure 2 and Table 3).  
Table 3. Relative mRNA expression levels of CD1d spliced variants, V4 and V5, in 
each group of patients. 
CD1d
Isoform Group 
Number of 
Samples
Relative mRNA Expression
CT (Mean) 2CT(Geometric mean) P Value
V4 NUD 49 -8.54 0.0027 <0.05* 
PUD 51 -8.79 0.0022 <0.01** 
 GC 37 -6.32 0.0125 
V5 NUD 48 -9.42 0.0015 <0.001*** 
PUD 51 -9.32 0.0016 <0.001*** 
 GC 37 -4.92 0.0330 
 Relative expression levels of V4 in NUD patients were significantly lower than those in GC group(p<0.05).٭ 
** Relative gene expression levels of V4 in PUD patients were significantly lower than those in GC group(p<0.01)
*** Relative gene expression levels of V5 in both NUD and PUD patients were significantly lower than those in GC group 
(p<0.001).
Moreover, GC patients showed higher expression levels of V5 compared to NUD and 
PUD groups (p<0.001 and p<0.001, respectively) (Figure 2 and Table 3). There was no 
significant difference between NUD and PUD groups regarding V4 or V5 expression 
levels. Amplification plots of quantitative real-time PCR with designed primers for V2 
produced late Ct on and were inconsistent. Therefore, we failed to determine the relative 
expression levels of V2. 
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Figure 2. Relative gene expression levels (CT) of CD1d spliced variants, V4 (A) and V5 (B), in 
patients with NUD, PUD, and GC. 
 
 
 
Increased Expression of V4, but not V5, in H. pylori-positive NUD Patients. 
Relative expression levels  of  V4  and V5 were further analyzed between H. pylori­
positive and -negative patients in each group of NUD, PUD, and GC. The results 
showed that among NUD patients, relative gene expression levels of V4 in H. pylori­
positive patients were significantly higher than those in H. pylo ri-negative ones 
(p<0.01) (Figure 3A and Table 4). 
 
 
Table 4. Relative mRNA expression levels of CD1d spliced variants, V4 and V5, in 
each group of patients regarding H. pylori infection. 
 
CD1d 
Isofor m Group H. pylori Num Sam 
ber of 
ples C 
Relative m 
T (Mean) 
RNA Expre 
2CT (Geom 
ssion 
etric mean) 
P Value 
NUD Positi Negati 
ve 
ve 
3 
1 
0 
9 
-7.62 
-10.07 
0.00 
0.00 
50 
09 0.004** 
V4 PUD Positi Negati 
ve 
ve 
3 
1 
6 
5 
-8.21 
-9.99 
0.00 
0.00 
34 
10 0.119 
GC Positi Negati 
ve 
ve 
2 
1 
0 
7 
-6.24 
-6.35 
0.01 
0.01 
32 
22 0.715 
NUD Positi Negati 
ve 
ve 
2 
1 
9 
9 
-8.58 
-11.21 
0.00 
0.00 
26 
04 0.084 
V5 PUD Positi Negati 
ve 
ve 
3 
1 
6 
5 
-9.13 
-10.02 
0.00 
0.00 
18 
10 0.444 
GC Positi Negati 
ve 
ve 
2 
1 
0 
7 
-4.43 
-5.41 
0.04 
0.02 
64 
34 0.345 
** The expression levels of V4 were significantly higher in H. pylori-positive NUD patients than in H. pylori-negative ones 
(P<0.01). 
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However, there was no significant difference between H. pylori-positive and -negative 
patients in PUD and GC groups regarding V4 expression (Figure 3A and Table 4). 
Moreover, the expression levels of V5 were not significantly different between H. 
pylori-positive and -negative patients in none of NUD, PUD, or GC groups (Figure 3B 
and Table 4). 
 
Figure 3. Relative gene expression levels (CT) of CD1d spliced variants, V4 (A) and V5 (B) in 
H. pylori+ and H. pylori˗ patients with NUD, PUD, and GC. 
 
 
 
Positive Correlations between V4 and V5 Expression.The strength of association 
between the expression levels of V4 and V5 was further analyzed using the Spearman 
rank order correlation test, and the correlation coefficient was calculated. 
 
 
 
Figure 4. Linear Correlations between the expression levels (CT) of V4 and V5 in patients with 
PUD (r=0.734, p<0.0001) and GC (r=0.423, p<0.01). 
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Positive correlation coefficients were attained between V4 and V5 expression in 
patients with PUD (r=0.734, p<0.0001) and GC (r=0.423, p<0.01) but not in patients 
with NUD (Figure 4). 
DISCUSSION 
The present study showed that the expression levels of two alternatively spliced variants 
of CD1d, V4 and V5,were significantly higher in patients with gastric cancer than those
with non-malignant inflamed gastric mucosa, NUD and PUD. Moreover, the expression 
levels of V4 and V5 were significantly correlated with each other in GC patients.
Previous studies on the expression of CD1d on the surface of tumor cells and its role in 
the presentation of tumor antigens have reported opposing results. Some studies have 
reported an up-regulation of CD1d in several types of tumors, such as glioma (16), 
medulloblastoma (17), prostate Cancer (18), and some types of leukemia (19,20). 
Moreover, tumor cells expressing functional CD1d have been targeted for direct NKT-
cell cytotoxicity using either synthetic NKT ligands or ex-vivo expanded NKT cells 
(21). For instance, α-GalactosylCeramid (α-GalCer), as a synthetic ligand, can stimulate 
NKT cells in a CD1d dependent manner, which results in production of Interferon 
(IFN)- and Interleukin (IL)-4, demonstrating α-GalCer as an important antitumor
stimulator in different tumor models (22). 
In contrast, some other studies have reported that the majority of solid tumors were 
CD1d negative (23). One study showed the down-regulation of CD1d on breast cancer 
cells, which led to inhibition of iNKT cell-mediated antitumor immunity, and promoting 
breast cancer metastasis (24). Another study revealed the lower expression levels of 
CD1d by omental hematopoietic cells and the lower number of iNKT cells in colon 
cancer patients compared to healthy controls (25). Moreover, down-regulation of CD1d 
molecule in patients with malignant lymphoma has led to reduced expansion of iNKT 
cells (26). Therefore, it seems that up- or down-regulation of CD1d molecule affects
anti-tumor iNKT cell response in different ways. In the present study, in contrast to the 
previous studies, three alternative spliced variants of CD1d, including V2, V4, and V5, 
were selected to be investigated, since all three variants contain intact α1 and α2 
domains which form antigen-binding region making these variants capable of presenting 
glycolipid antigens. If we assume that CD1d-associated presentation of tumor antigens,
such as GD3 and glycosphingolipids, to iNKT cells can lead to an anti-tumor immune 
response, how can the gastric tumor develop while both V4 and V5 are over-expressed 
in the gastric mucosa? One explanation could be that although up-regulation of V4, as a
membranous form of CD1d presenting tumor associated glycolipid antigens, leads to 
iNKT cell activation, simultaneous binding of V5, as a soluble form of CD1d, to the 
same antigens, might act as a competitive inhibitor for the V4. Therefore, up-regulation 
of V5 might be a mechanism by which tumor cells could evade the innate immune 
system. On the other hand, Kojo et al. in 2000 reported that variants of CD1d without
α3 domain might be unstable presented on the cell surface (27). Therefore, given that 
V4 lacks α3 domain, it might be unstably presented on the surface of gastric epithelial 
cells, which, in turn, leads to inadequate activation of NKT cells. Another explanation 
could be that over-expression of CD1d variants does not necessarily lead to increase 
iNKT cell responses against tumor, as many studies have shown that the number and 
function of these cells were reduced in the several types of cancers (18,19,28).  
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We further compared the expression levels of V4 and V5 between H. pylori-positive
and-negative samples in each group of NUD, PUD, and GC. The results showed that the
expression levels of V4, but not V5, were significantly higher in H. pylori-positive
NUD patients than those in H. pylori -negative ones. In contrast to NUD patients, 
comparison of the expression levels of V4 and V5 in H. pylori-positive and -negative 
PUD and GC patients showed no significant difference. Therefore, the over-expression 
of V4, as a membranous isoform of CD1d, in H. pylori-positive NUD patients might be 
a mechanism to increase presentation of bacterial lipid antigens to iNKT cells and
stimulates innate immune responses against infection. In this regard, it has been shown 
that cholesteryl α-glucoside, the major component of H. pylori cell wall lipids, could 
interact with CD1d and contribute to induction of iNKT cell responses (9) suggesting 
that CD1d is able to present H. pylori antigens to iNKT cells. Under malignant 
circumstance of gastric cancer, however, it seems that the over-expression of CD1d 
variants is independent of H. pylori infection. Probably, tumor antigens, like tumor-
associated altered glycolipid ligands, dominate H. pylori antigens in iNKT cell 
activation. Concurrently, GD3, a ganglioside that is highly expressed by human tumors 
of different origins, has been shown to be recognized by mouse NKT cells in a CD1d­
restricted manner (29). In addition, CD1d has been reported to be involved in the 
presentation of inflammation-associated lyso-phospholipids from the plasma of 
myeloma patients to CD1d-restricted T cells (30).
We failed to determine the relative expression levels of V2, as V2 produced late Ct on 
amplification plot and was inconsistent. We believe that this shows very low levels of 
V2 expression, as it was also reported by Benam et al. (15). 
In summary, this study, for the first time, determined the expression levels of the three 
alternative spliced variants of CD1d, which probably preserved their antigen-binding
groove, in human gastric mucosa. An over-expression of both membranous isoforms, 
V4, and soluble isoform,V5, of CD1d was observed in gastric tumor tissues. Moreover, 
the expression levels of V4 and V5 were significantly correlated with each other in GC 
patients. We thus hypothesize that although the membranous form of CD1d can present 
glycolipid antigens and stimulates an anti-tumor immune response, the soluble form
binds to iNKT cell receptors and finally inhibits the iNKT cell response. We also found 
out a V4 over-expression in H. pylori-positive NUD patients compared to H. pylori-
negative ones suggesting the role of V4 in presentation of H. pylori antigens in inflamed 
gastric mucosa. In gastric tumor samples, however, CD1d expression seems to be 
independent of H. pylori infection, since it is implicated predominantly in the
presentation of altered glycolipid ligands associated with tumor. In future, we suggest 
investigating the role of different variants of CD1d in proliferation of iNKT cells in 
vitro, and also possible correlations between the expression levels of CD1d spliced 
variants and the frequency and function of iNKT cells in gastric epithelial layer. 
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